IMI announces conference call and webcast to discuss worldwide licensing agreement with McNeil Consumer Healthcare to market car

IMI announces conference call and webcast to discuss worldwide
licensing agreement with McNeil Consumer Healthcare to market cardiovascular
disease test 


TORONTO, June 1  /PRNewswire-FirstCall/ -- Late on Friday, May 28, 2004, IMI
International Medical Innovations Inc. (Amex: IME; TSX:IMI), a world leader in
predictive medicine, together with its wholly-owned Swiss subsidiary, concluded
an exclusive worldwide non-Canadian licensing agreement with McNeil Consumer
Healthcare, a Johnson & Johnson company (NYSE:JNJ), for IMI's non-invasive
cardiovascular risk assessment technology. McNeil and its worldwide affiliates
will market and distribute IMI's predictive tests for coronary artery disease
under the brand name PREVU(x) Coronary Heart Disease Predictor.

Under the financial terms of the agreement, IMI will sell products to McNeil
and receive an ongoing royalty on McNeil's sales of those products. IMI will
also receive a $3.0-million up-front payment as well as a series of milestone
payments of up to approximately $15.75 million. This amount is in addition to
$3.3 million in milestone payments from IMI's existing Canadian license
agreement.

  -------------------------------------------------------------------------
  Conference Call and Webcast
  IMI will hold a conference call and webcast today, June 1, 2004, at
  10 a.m. ET. To access the conference call, please dial [phone] in
  Toronto, or 1-800-814-4860 elsewhere in North America. A live audio
  webcast will be available at http://www.imimedical.com/ or
http://www.newswire.ca/ and
  subsequently archived on both sites. To access the replay via telephone,
  which will be available until June 8, 2004, please dial [phone] or
  1-877-289-8525 and enter the passcode 21051734.

  B-Roll Coordinates
  Television stations can downlink a b-roll on June 1, 2004 from
  10 a.m. (ET) to 10:15 a.m. (ET). Satellite coordinates are:
  AMC 9, Transponder 4
  Audio subcarrier 6.2 and 6.8
  Downlink frequency 3780 horizontal
  -------------------------------------------------------------------------

  About IMI


IMI is a world leader in predictive medicine, dedicated to developing rapid,
non-invasive tests for the early detection of life-threatening diseases,
particularly cardiovascular disease and cancer. The company's head office is
located in Toronto, and its research and product development facility is at
McMaster University in Hamilton, Ontario. For further information, please visit
the company's website at http://www.imimedical.com/.

  This release contains forward-looking statements that reflect the
  company's current expectations regarding future events. The forward-
  looking statements involve risks and uncertainties. Actual events could
  differ materially from those projected herein and depend on a number of
  factors including, but not limited to, changing market conditions,
  successful and timely completion of clinical studies, uncertainties
  related to the regulatory approval process, establishment of corporate
  alliances and other risks detailed from time to time in the company's
  quarterly, annual and other regular filings.


DATASOURCE: IMI International Medical Innovations Inc.



CONTACT: Brent Norton, President and CEO; Sarah Borg-Olivier, Director,

Communications; Ron Hosking, Vice President, Finance and CFO; [phone],

Copyright